Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) just unveiled an update.
Lumos Diagnostics has issued an addendum to its Notice of Annual General Meeting, addressing shareholder queries regarding the timing and vesting conditions of performance rights for its CEO, Douglas Ward. The addendum does not alter the validity of previously submitted proxy votes and provides shareholders with additional details to consider before the meeting on October 24, 2025.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.
Average Trading Volume: 8,250,051
Technical Sentiment Signal: Buy
Current Market Cap: A$141.5M
Learn more about LDX stock on TipRanks’ Stock Analysis page.